Cantitate/Preț
Produs

Resistance to Targeted Therapies in Breast Cancer: Resistance to Targeted Anti-Cancer Therapeutics, cartea 16

Editat de Jenifer R. Prosperi
en Limba Engleză Hardback – 13 dec 2017
We present an in-depth description of resistance to targeted therapies in breast cancer. Targeted therapies discussed here include those used to treat ER+ or Her2+ breast cancers (i.e., Tamoxifen or trastuzumab) or those targeting signaling pathways aberrantly activated in triple negative breast cancer (i.e., EGFR and Wnt signaling). We have also provided an overview of standard of care as an introduction into the importance of targeted therapy. It is our hope that this volume gives an insight into the landscape of breast cancer treatment, the challenges of targeted therapy, and a glimpse into the future of breast cancer therapy.
Citește tot Restrânge

Toate formatele și edițiile

Toate formatele și edițiile Preț Express
Paperback (1) 75803 lei  6-8 săpt.
  Springer International Publishing – 23 iun 2018 75803 lei  6-8 săpt.
Hardback (1) 107388 lei  6-8 săpt.
  Springer International Publishing – 13 dec 2017 107388 lei  6-8 săpt.

Din seria Resistance to Targeted Anti-Cancer Therapeutics

Preț: 107388 lei

Preț vechi: 113040 lei
-5% Nou

Puncte Express: 1611

Preț estimativ în valută:
20552 21348$ 17071£

Carte tipărită la comandă

Livrare economică 03-17 februarie 25

Preluare comenzi: 021 569.72.76

Specificații

ISBN-13: 9783319701417
ISBN-10: 331970141X
Pagini: 286
Ilustrații: XV, 184 p. 12 illus.
Dimensiuni: 155 x 235 mm
Greutate: 0.46 kg
Ediția:1st ed. 2017
Editura: Springer International Publishing
Colecția Springer
Seria Resistance to Targeted Anti-Cancer Therapeutics

Locul publicării:Cham, Switzerland

Cuprins

Invasive Breast Cancer Therapy 2017: How Well Are We Hitting The Target?.- Resistance to HER2-targeted therapy.- Endocrine Resistance and Breast Cancer Stem Cells – The Inflammatory Connection That Could Lead to New and Improved Therapy Outcomes.- EGFR Resistance.- Targeting FGFR for the treatment of breast cancer.- Targeted Therapies in Breast Cancer.- Future paradigm of breast cancer resistance and treatment.

Notă biografică

Dr. Prosperi received her BA in Microbiology from Miami University (OH), and went on to get a PhD in Integrated Biomedical Science (focus: Cancer Biology) at The Ohio State University. She joined a laboratory focused on breast cancer research, and started volunteering at The James Cancer Hospital and with The Komen Foundation. She then completed postdoctoral studies at the University of Chicago, where she started to focus on the APC tumor suppressor and developing targeted therapies for breast cancer. In 2012, she was recruited to Indiana University School of Medicine – South Bend with an adjunct faculty position at the University of Notre Dame. Through these affiliations, she has been a member of both the Simon Cancer Center and the Harper Cancer Research Institute since 2012. Her laboratory is focused on the understanding of resistance to chemotherapy in breast cancer patients, specifically how the APC tumor suppressor impacts this process.

Textul de pe ultima copertă

We present an in-depth description of resistance to targeted therapies in breast cancer. Targeted therapies discussed here include those used to treat ER+ or Her2+ breast cancers (i.e., Tamoxifen or trastuzumab) or those targeting signaling pathways aberrantly activated in triple negative breast cancer (i.e., EGFR and Wnt signaling). We have also provided an overview of standard of care as an introduction into the importance of targeted therapy. It is our hope that this volume gives an insight into the landscape of breast cancer treatment, the challenges of targeted therapy, and a glimpse into the future of breast cancer therapy.  


Caracteristici

This book will provide an in-depth description of resistance to targeted therapies in breast cancer This book will discuss targeted therapies used to treat ER+ or Her2+ breast cancers (i.e. Tamoxifen or trastuzumab) This book will also discuss targeting signaling pathways activated in triple negative breast cancer (i.e. EGFR and Wnt signaling) This book will give insight into the landscape of breast cancer treatment and the challenges of targeted therapy This book will provide a glimpse into the future of breast cancer therapy